Skip to main content
Erschienen in: International Orthopaedics 1/2015

01.01.2015 | Original Paper

Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation

verfasst von: Ju Ang Kim, Hye Jung Ihn, Ju-Young Park, Jiwon Lim, Jung Min Hong, Sang Hyun Kim, Shin-Yoon Kim, Hong-In Shin, Eui Kyun Park

Erschienen in: International Orthopaedics | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We examined the effects of triptolide on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation and on titanium (Ti) particle-induced osteolysis.

Methods

To examine the effect of triptolide on osteoclast differentiation, bone marrow macrophages (BMMs) were treated with 100 ng/mL of RANKL and 30 ng/mL of macrophage-colony stimulating factor, or co-cultured with osteoblasts stimulated with 10 nM vitamin D3 and 1 μM prostaglandin E2 in the presence or absence of triptolide (2.8–14 nM). Osteoclast differentiation and activation were assessed using tartrate-resistant acid phosphatase staining, reverse transcriptase-polymerase chain reaction analysis to determine differentiation marker gene expression and pit formation assays. To examine the effect of triptolide on wear debris-induced osteolysis, titanium (Ti) particles were injected into the calvaria of ICR mice. Then, the mice were divided into three groups and were orally administered vehicle, or 16 or 32 μg/kg/day triptolide for ten days, followed by histomorphometric analysis.

Results

Triptolide suppressed RANKL-mediated osteoclast differentiation of BMMs in a dose-dependent manner. In a co-culture system, osteoblasts treated with triptolide could not induce osteoclast differentiation of BMMs, which was accompanied by down-regulation of RANKL and up-regulation of osteoprotegrin. Moreover, triptolide significantly inhibited bone resorption, and expression of the bone resorption marker genes. RANKL-induced activation of p38, ERK, and JNK was substantially inhibited by triptolide. Further, in a Ti-induced mouse calvarial erosion model, mice perorally administrated with triptolide showed significant attenuation of Ti-mediated osteolysis.

Conclusion

Our data indicated that triptolide had an anti-osteoclastic effect and significantly suppressed wear debris-induced osteolysis in mice.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wang J, Wang A, Zeng H, Liu L, Jiang W, Zhu Y, Xu Y (2012) Effect of triptolide on T-cell receptor beta variable gene mRNA expression in rats with collagen-induced arthritis. Anat Rec 295(6):922–927CrossRef Wang J, Wang A, Zeng H, Liu L, Jiang W, Zhu Y, Xu Y (2012) Effect of triptolide on T-cell receptor beta variable gene mRNA expression in rats with collagen-induced arthritis. Anat Rec 295(6):922–927CrossRef
2.
Zurück zum Zitat Xue M, Jiang ZZ, Liu JP, Zhang LY, Wang T, Wang H, Liu L, Zhou ZX (2010) Comparative study on the anti-inflammatory and immune suppressive effect of Wilforlide A. Fitoterapia 81(8):1109–1112PubMedCrossRef Xue M, Jiang ZZ, Liu JP, Zhang LY, Wang T, Wang H, Liu L, Zhou ZX (2010) Comparative study on the anti-inflammatory and immune suppressive effect of Wilforlide A. Fitoterapia 81(8):1109–1112PubMedCrossRef
3.
Zurück zum Zitat Kupchan SM, Court WA, Dailey RG Jr, Gilmore CJ, Bryan RF (1972) Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 94(20):7194–7195PubMedCrossRef Kupchan SM, Court WA, Dailey RG Jr, Gilmore CJ, Bryan RF (1972) Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 94(20):7194–7195PubMedCrossRef
4.
Zurück zum Zitat Wong KF, Yuan Y, Luk JM (2012) Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 39(3):311–320PubMedCrossRef Wong KF, Yuan Y, Luk JM (2012) Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 39(3):311–320PubMedCrossRef
5.
Zurück zum Zitat Wu Y, Cui J, Bao X, Chan S, Young DO, Liu D, Shen P (2006) Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med 17(1):141–150PubMed Wu Y, Cui J, Bao X, Chan S, Young DO, Liu D, Shen P (2006) Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med 17(1):141–150PubMed
6.
Zurück zum Zitat Qiu D, Kao PN (2003) Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 4(1):1–18PubMedCrossRef Qiu D, Kao PN (2003) Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 4(1):1–18PubMedCrossRef
7.
Zurück zum Zitat Liu Q (2011) Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 11(3):377–383PubMedCrossRef Liu Q (2011) Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 11(3):377–383PubMedCrossRef
8.
Zurück zum Zitat Xue X, Gong L, Qi X, Wu Y, Xing G, Yao J, Luan Y, Xiao Y, Li Y, Wu X, Chen M, Gu J, Ren J (2011) Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Toxicol Lett 205(1):47–54PubMedCrossRef Xue X, Gong L, Qi X, Wu Y, Xing G, Yao J, Luan Y, Xiao Y, Li Y, Wu X, Chen M, Gu J, Ren J (2011) Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Toxicol Lett 205(1):47–54PubMedCrossRef
9.
Zurück zum Zitat Li J, Jin J, Li M, Guan C, Wang W, Zhu S, Qiu Y, Huang M, Huang Z (2012) Role of Nrf2 in protection against triptolide-induced toxicity in rat kidney cells. Toxicol Lett 213(2):194–202PubMedCrossRef Li J, Jin J, Li M, Guan C, Wang W, Zhu S, Qiu Y, Huang M, Huang Z (2012) Role of Nrf2 in protection against triptolide-induced toxicity in rat kidney cells. Toxicol Lett 213(2):194–202PubMedCrossRef
10.
Zurück zum Zitat Ye X, Li W, Yan Y, Mao C, Cai R, Xu H, Yang X (2010) Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett 192(2):212–220PubMedCrossRef Ye X, Li W, Yan Y, Mao C, Cai R, Xu H, Yang X (2010) Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat. Toxicol Lett 192(2):212–220PubMedCrossRef
11.
Zurück zum Zitat Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y, Xu H, Yang X (2004) A study of microemulsion systems for transdermal delivery of triptolide. J Control Release 98(3):427–436PubMedCrossRef Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y, Xu H, Yang X (2004) A study of microemulsion systems for transdermal delivery of triptolide. J Control Release 98(3):427–436PubMedCrossRef
12.
Zurück zum Zitat Xu F, Shi X, Li S, Cui J, Lu Z, Jin Y, Lin Y, Pang J, Pan J (2010) Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl. Bioorg Med Chem 18(5):1806–1815PubMedCrossRef Xu F, Shi X, Li S, Cui J, Lu Z, Jin Y, Lin Y, Pang J, Pan J (2010) Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl. Bioorg Med Chem 18(5):1806–1815PubMedCrossRef
13.
Zurück zum Zitat Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, Rosen GD (2003) PG 490–88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2(9):855–862PubMed Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M, Rosen GD (2003) PG 490–88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2(9):855–862PubMed
14.
Zurück zum Zitat Aoyagi Y, Hitotsuyanagi Y, Hasuda T, Matsuyama S, Fukaya H, Takeya K, Aiyama R, Matsuzaki T, Hashimoto S (2008) Fluorination of triptolide and its analogues and their cytotoxicity. Bioorg Med Chem Lett 18(7):2459–2463PubMedCrossRef Aoyagi Y, Hitotsuyanagi Y, Hasuda T, Matsuyama S, Fukaya H, Takeya K, Aiyama R, Matsuzaki T, Hashimoto S (2008) Fluorination of triptolide and its analogues and their cytotoxicity. Bioorg Med Chem Lett 18(7):2459–2463PubMedCrossRef
15.
Zurück zum Zitat Zhou ZL, Yang YX, Ding J, Li YC, Miao ZH (2012) Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep 29(4):457–475PubMedCrossRef Zhou ZL, Yang YX, Ding J, Li YC, Miao ZH (2012) Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep 29(4):457–475PubMedCrossRef
16.
Zurück zum Zitat Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, Saluja AK (2012) A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med 4(156):156ra139PubMedCentralPubMedCrossRef Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, Saluja AK (2012) A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med 4(156):156ra139PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Dumbleton JH, Manley MT, Edidin AA (2002) A literature review of the association between wear rate and osteolysis in total hip arthroplasty. J Arthroplasty 17(5):649–661PubMedCrossRef Dumbleton JH, Manley MT, Edidin AA (2002) A literature review of the association between wear rate and osteolysis in total hip arthroplasty. J Arthroplasty 17(5):649–661PubMedCrossRef
18.
Zurück zum Zitat Goldring SR, Schiller AL, Roelke M, Rourke CM, O’Neil DA, Harris WH (1983) The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am 65(5):575–584PubMed Goldring SR, Schiller AL, Roelke M, Rourke CM, O’Neil DA, Harris WH (1983) The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am 65(5):575–584PubMed
19.
Zurück zum Zitat Jin S, Park JY, Hong JM, Kim TH, Shin HI, Park EK, Kim SY (2011) Inhibitory effect of (-)-epigallocatechin gallate on titanium particle-induced TNF-alpha release and in vivo osteolysis. Exp Mol Med 43(7):411–418PubMedCentralPubMedCrossRef Jin S, Park JY, Hong JM, Kim TH, Shin HI, Park EK, Kim SY (2011) Inhibitory effect of (-)-epigallocatechin gallate on titanium particle-induced TNF-alpha release and in vivo osteolysis. Exp Mol Med 43(7):411–418PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL (1999) Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 154(1):203–210PubMedCentralPubMedCrossRef Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL (1999) Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 154(1):203–210PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT (1995) Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty 10(4):498–506PubMedCrossRef Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT (1995) Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty 10(4):498–506PubMedCrossRef
22.
Zurück zum Zitat Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP (2007) The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 454:251–261PubMedCrossRef Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP (2007) The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 454:251–261PubMedCrossRef
23.
Zurück zum Zitat Ren W, Wu B, Peng X, Hua J, Hao HN, Wooley PH (2006) Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK(−/−) mice. J Orthop Res 24(8):1575–1586PubMedCrossRef Ren W, Wu B, Peng X, Hua J, Hao HN, Wooley PH (2006) Implant wear induces inflammation, but not osteoclastic bone resorption, in RANK(−/−) mice. J Orthop Res 24(8):1575–1586PubMedCrossRef
24.
Zurück zum Zitat Ingham E, Fisher J (2005) The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11):1271–1286PubMedCrossRef Ingham E, Fisher J (2005) The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11):1271–1286PubMedCrossRef
25.
Zurück zum Zitat Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, Lee MS, Kim JJ, Bae JM, Kim SH, Kim HS (2010) Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 46(3):724–731PubMedCrossRef Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, Lee MS, Kim JJ, Bae JM, Kim SH, Kim HS (2010) Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 46(3):724–731PubMedCrossRef
26.
Zurück zum Zitat Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342PubMedCrossRef Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342PubMedCrossRef
27.
Zurück zum Zitat Cappellen D, Luong-Nguyen NH, Bongiovanni S, Grenet O, Wanke C, Susa M (2002) Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 277(24):21971–21982PubMedCrossRef Cappellen D, Luong-Nguyen NH, Bongiovanni S, Grenet O, Wanke C, Susa M (2002) Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 277(24):21971–21982PubMedCrossRef
28.
Zurück zum Zitat Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20(6):1271–1280PubMedCentralPubMedCrossRef Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20(6):1271–1280PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K (2002) U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277(49):47366–47372PubMedCrossRef Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, Yoshida N, Nakayama K (2002) U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 277(49):47366–47372PubMedCrossRef
30.
Zurück zum Zitat Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF (2004) Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279(25):26475–26480PubMedCrossRef Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF (2004) Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279(25):26475–26480PubMedCrossRef
31.
Zurück zum Zitat Nakashima T, Takayanagi H (2009) Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 29(5):555–567PubMedCrossRef Nakashima T, Takayanagi H (2009) Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 29(5):555–567PubMedCrossRef
32.
Zurück zum Zitat Zhao Q, Wang X, Liu Y, He A, Jia R (2010) NFATc1: functions in osteoclasts. Int J Biochem Cell Biol 42(5):576–579PubMedCrossRef Zhao Q, Wang X, Liu Y, He A, Jia R (2010) NFATc1: functions in osteoclasts. Int J Biochem Cell Biol 42(5):576–579PubMedCrossRef
33.
Zurück zum Zitat Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK (2009) A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun 378(3):645–649PubMedCrossRef Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK (2009) A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun 378(3):645–649PubMedCrossRef
34.
Zurück zum Zitat Park EK, Lee YE, Choi JY, Oh SH, Shin HI, Kim KH, Kim SY, Kim S (2004) Cellular biocompatibility and stimulatory effects of calcium metaphosphate on osteoblastic differentiation of human bone marrow-derived stromal cells. Biomaterials 25(17):3403–3411PubMedCrossRef Park EK, Lee YE, Choi JY, Oh SH, Shin HI, Kim KH, Kim SY, Kim S (2004) Cellular biocompatibility and stimulatory effects of calcium metaphosphate on osteoblastic differentiation of human bone marrow-derived stromal cells. Biomaterials 25(17):3403–3411PubMedCrossRef
35.
Zurück zum Zitat Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL (2003) c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 111(5):749–758PubMedCentralPubMedCrossRef Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL (2003) c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 111(5):749–758PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Battaglino R, Kim D, Fu J, Vaage B, Fu XY, Stashenko P (2002) c-myc is required for osteoclast differentiation. J Bone Miner Res 17(5):763–773PubMedCrossRef Battaglino R, Kim D, Fu J, Vaage B, Fu XY, Stashenko P (2002) c-myc is required for osteoclast differentiation. J Bone Miner Res 17(5):763–773PubMedCrossRef
37.
Zurück zum Zitat Vukosavic S, Stefanis L, Jackson-Lewis V, Guegan C, Romero N, Chen C, Dubois-Dauphin M, Przedborski S (2000) Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 20(24):9119–9125PubMed Vukosavic S, Stefanis L, Jackson-Lewis V, Guegan C, Romero N, Chen C, Dubois-Dauphin M, Przedborski S (2000) Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 20(24):9119–9125PubMed
38.
Zurück zum Zitat Choi YA, Lim J, Kim KM, Acharya B, Cho JY, Bae YC, Shin HI, Kim SY, Park EK (2010) Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation. J Proteome Res 9(6):2946–2956PubMedCrossRef Choi YA, Lim J, Kim KM, Acharya B, Cho JY, Bae YC, Shin HI, Kim SY, Park EK (2010) Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation. J Proteome Res 9(6):2946–2956PubMedCrossRef
39.
Zurück zum Zitat Wu Y, Wang Y, Zhong C, Li Y, Li X, Sun B (2003) The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response. Int Immunopharmacol 3(10–11):1457–1465PubMedCrossRef Wu Y, Wang Y, Zhong C, Li Y, Li X, Sun B (2003) The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response. Int Immunopharmacol 3(10–11):1457–1465PubMedCrossRef
40.
Zurück zum Zitat Wang Y, Jia L, Wu CY (2008) Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scand J Immunol 68(4):383–390PubMedCrossRef Wang Y, Jia L, Wu CY (2008) Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scand J Immunol 68(4):383–390PubMedCrossRef
41.
Zurück zum Zitat Li Y, Yu C, Zhu WM, Xie Y, Qi X, Li N, Li JS (2010) Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Mol Immunol 47(15):2467–2474PubMedCrossRef Li Y, Yu C, Zhu WM, Xie Y, Qi X, Li N, Li JS (2010) Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Mol Immunol 47(15):2467–2474PubMedCrossRef
42.
Zurück zum Zitat Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, Li LS, Liu ZH (2010) Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 77(11):974–988PubMedCrossRef Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, Li LS, Liu ZH (2010) Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 77(11):974–988PubMedCrossRef
43.
Zurück zum Zitat Liu C, Zhang Y, Kong X, Zhu L, Pang J, Xu Y, Chen W, Zhan H, Lu A, Lin N (2013) Triptolide prevents bone destruction in the collagen-induced arthritis model of rheumatoid arthritis by targeting RANKL/RANK/OPG signal pathway. Evid Based Complement Alternat Med 2013:626038PubMedCentralPubMed Liu C, Zhang Y, Kong X, Zhu L, Pang J, Xu Y, Chen W, Zhan H, Lu A, Lin N (2013) Triptolide prevents bone destruction in the collagen-induced arthritis model of rheumatoid arthritis by targeting RANKL/RANK/OPG signal pathway. Evid Based Complement Alternat Med 2013:626038PubMedCentralPubMed
44.
Zurück zum Zitat Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U (2012) Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol 74(3):424–436PubMedCentralPubMedCrossRef Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U (2012) Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol 74(3):424–436PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, Somlo S, Crews CM (2007) Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 104(11):4389–4394PubMedCentralPubMedCrossRef Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, Somlo S, Crews CM (2007) Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 104(11):4389–4394PubMedCentralPubMedCrossRef
46.
Zurück zum Zitat McCallum C, Kwon S, Leavitt P, Shen DM, Liu W, Gurnett A (2007) Triptolide binds covalently to a 90 kDa nuclear protein. Role of epoxides in binding and activity. Immunobiology 212(7):549–556PubMedCrossRef McCallum C, Kwon S, Leavitt P, Shen DM, Liu W, Gurnett A (2007) Triptolide binds covalently to a 90 kDa nuclear protein. Role of epoxides in binding and activity. Immunobiology 212(7):549–556PubMedCrossRef
47.
Zurück zum Zitat Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y, Smeaton M, Demain AL, Miller PS, Kugel JF, Goodrich JA, Liu JO (2011) XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 7(3):182–188PubMedCentralPubMedCrossRef Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y, Smeaton M, Demain AL, Miller PS, Kugel JF, Goodrich JA, Liu JO (2011) XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 7(3):182–188PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Hercus B, Saeed S, Revell PA (2002) Expression profile of T cell associated molecules in the interfacial tissue of aseptically loosened prosthetic joints. J Mater Sci Mater Med 13(12):1153–1156PubMedCrossRef Hercus B, Saeed S, Revell PA (2002) Expression profile of T cell associated molecules in the interfacial tissue of aseptically loosened prosthetic joints. J Mater Sci Mater Med 13(12):1153–1156PubMedCrossRef
49.
Zurück zum Zitat Al-Saffar N, Khwaja HA, Kadoya Y, Revell PA (1996) Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants. Am J Clin Pathol 105(5):628–639PubMed Al-Saffar N, Khwaja HA, Kadoya Y, Revell PA (1996) Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants. Am J Clin Pathol 105(5):628–639PubMed
50.
Zurück zum Zitat Cano E, Mahadevan LC (1995) Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20(3):117–122PubMedCrossRef Cano E, Mahadevan LC (1995) Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20(3):117–122PubMedCrossRef
51.
Zurück zum Zitat Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR (2004) Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 25(4):565–573PubMedCrossRef Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR (2004) Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 25(4):565–573PubMedCrossRef
52.
Zurück zum Zitat Zhou B, Li X, Tang H, Miao Z, Feng H, Li Y (2011) Total synthesis of novel D-ring-modified triptolide analogues: structure-cytotoxic activity relationship studies on the D-ring of triptolide. Org Biomol Chem 9(9):3176–3179PubMedCrossRef Zhou B, Li X, Tang H, Miao Z, Feng H, Li Y (2011) Total synthesis of novel D-ring-modified triptolide analogues: structure-cytotoxic activity relationship studies on the D-ring of triptolide. Org Biomol Chem 9(9):3176–3179PubMedCrossRef
53.
Zurück zum Zitat Kupchan SM, Schubert RM (1974) Selective alkylation: a biomimetic reaction of the antileukemic triptolides? Science 185(4153):791–793PubMedCrossRef Kupchan SM, Schubert RM (1974) Selective alkylation: a biomimetic reaction of the antileukemic triptolides? Science 185(4153):791–793PubMedCrossRef
54.
Zurück zum Zitat Zhang C, Peng F, Liu W, Wan J, Wan C, Xu H, Lam CW, Yang X (2014) Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J Nanomedicine 9:1049–1063PubMedCentralPubMed Zhang C, Peng F, Liu W, Wan J, Wan C, Xu H, Lam CW, Yang X (2014) Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J Nanomedicine 9:1049–1063PubMedCentralPubMed
Metadaten
Titel
Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation
verfasst von
Ju Ang Kim
Hye Jung Ihn
Ju-Young Park
Jiwon Lim
Jung Min Hong
Sang Hyun Kim
Shin-Yoon Kim
Hong-In Shin
Eui Kyun Park
Publikationsdatum
01.01.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
International Orthopaedics / Ausgabe 1/2015
Print ISSN: 0341-2695
Elektronische ISSN: 1432-5195
DOI
https://doi.org/10.1007/s00264-014-2596-3

Weitere Artikel der Ausgabe 1/2015

International Orthopaedics 1/2015 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.